Core Insights - TOMI Environmental Solutions, Inc. has announced a new service provider that will utilize its SteraMist iHP technology for mold and mycotoxins remediation in the healthcare sector, with an investment of approximately $185,500 in SteraMist mobile systems and BIT solution [1] - The new provider has secured a significant contract to remediate a 400,000-cubic-feet space at a hospital, which includes HVAC decontamination [1] - The partnership is expected to enhance TOMI's presence in the healthcare industry, leveraging the expertise of the new provider and its relationship with Enviro-Mist Inc., a long-standing partner specializing in mold remediation [2] Company Overview - TOMI Environmental Solutions, Inc. is a global company focused on decontamination and infection prevention, offering environmental solutions through its Binary Ionization Technology (BIT) platform [3] - BIT solution, developed under a defense grant with DARPA, utilizes a low percentage of hydrogen peroxide as its active ingredient and employs patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [3] - TOMI's products are applicable in various settings, including hospitals, biosafety labs, pharmaceutical facilities, and commercial buildings [3]

Core Insights - The U.S. FDA has expanded the permitted use of hydrogen peroxide as a secondary direct food additive, which presents growth opportunities for TOMI Environmental Solutions in the food industry [1][2][4] Company Overview - TOMI Environmental Solutions specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform, which employs food-grade hydrogen peroxide as its active ingredient [1][4] - The company's SteraMist technology is designed to ensure no detectable residues remain on food products, aligning with the new FDA regulations [3][4] Regulatory Changes - The FDA's new rule allows food-grade hydrogen peroxide that meets Food Chemicals Codex specifications to be used in food production, provided that any residues are removed before reaching consumers [2][4] - This regulatory change validates the safety and efficacy of TOMI's SteraMist iHP technology, which has been supported by scientific studies demonstrating rapid decomposition of hydrogen peroxide residues on treated produce [4] Market Opportunities - The updated FDA regulation opens various market verticals for TOMI, including food safety, transportation, storage, packaging, and pathogen reduction, enhancing food safety and extending the shelf life of food products [4]

Financial Data and Key Metrics Changes - The company reported a 40% increase in consumables revenue for 2025 compared to 2024, with a gross margin of approximately 60% [12] - Revenue growth over pre-COVID levels is at 38%, with product revenue and service revenue both showing growth [27][28] - Service revenue grew over 30% year over year, with a significant contribution from the life sciences and pharmaceutical sectors [36][29] Business Line Data and Key Metrics Changes - The company operates five divisions: biotechnology, food and beverage, commercial services, healthcare, and custom integration, each showing potential for growth [8][9] - The integrated mobile and service pipeline is around $21 million, with $7 million in active specific designs [33][29] Market Data and Key Metrics Changes - The market opportunity for the company's products spans billions in biotechnology, food and beverage, commercial services, and healthcare [7] - The global medical device market is valued at approximately $23.78 billion, growing at a CAGR of about 10% [41] Company Strategy and Development Direction - The company aims to capitalize on the shift away from ethylene oxide in the life sciences market, which presents a significant opportunity for growth [19] - The focus is on expanding service offerings and enhancing the sales team to address new applications of their technology [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the conversion of open opportunities, citing a strong pipeline and ongoing contracts [37] - The company is optimistic about the lifting of capital restraints and the growing interest in their products post-COVID [20] Other Important Information - The company has 32 granted patents and over 200 trademarks registered in 50 states and more than 30 countries [7] - Recent FDA rule changes broaden the permitted use of hydrogen peroxide, opening new market opportunities in food safety and production [40] Q&A Session Summary Question: How repeatable is the growth in service revenue, and which industries are driving it? - Management indicated that the most traction is in life sciences and pharmaceuticals, with contracts for service revenue expected to grow year over year [36] Question: What gives confidence in conversion time and win rates? - Management noted that many opportunities are already won, and the design process with clients can take time, but they are confident in conversion rates [37] Question: How effective is the system at decontaminating facilities exposed to measles, and can production ramp up? - The company can quickly ramp up production using their backpack system, depending on capital availability [39]

Core Insights - TOMI Environmental Solutions, Inc. is participating in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16 and 17, 2025, with a presentation by CEO Dr. Halden Shane [1] - The company specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [4] Company Overview - TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) focuses on providing environmental solutions for disinfection, utilizing its BIT platform, which was developed with the Defense Advanced Research Projects Agency (DARPA) [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - TOMI's products cater to a wide range of sectors, including hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and emergency services [4] Conference Details - The live webcast of TOMI's presentation will be available online, with a replay accessible afterward [2] - The iAccess Alpha conference features companies recommended by investors, providing opportunities for one-on-one meetings with TOMI [3]

Core Insights - TOMI Environmental Solutions, Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 8-10, 2025, in New York City [1][2] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [3] - The BIT solution utilizes a low percentage of hydrogen peroxide as its active ingredient and incorporates patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [3] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, schools, and commercial buildings [3]

Financial Data and Key Metrics Changes - In Q2 2025, total recognized revenue was approximately $1,000,000, a decline of 66% from $3,000,000 in Q2 2024, primarily due to customers deferring capital expenditure projects [14] - Service revenue for the quarter was $378,000, representing a 33% increase year-over-year, while service revenue for the first six months reached $955,000, a 299% increase [15] - Gross margin improved to 66% in Q2 2025, up from 62% in the same quarter last year, attributed to a favorable product mix [15] Business Line Data and Key Metrics Changes - Service revenue from IHP service deployments and validation support services grew by 33% compared to the same period last year and by 46% over the first six months [8] - BIT solution sales saw a 40% increase year-to-date, with expectations for continued growth due to repeat orders [10] - The company has a sales order backlog of approximately $4,600,000, with active projects scheduled for delivery in 2025 [7] Market Data and Key Metrics Changes - The company is negotiating approximately $2,000,000 in new custom and integrated contracts, with bids expected to close before year-end [7] - Open opportunities for three product offerings total approximately $15,000,000, with $7,000,000 designated as high priority [7] - The USDA increased its usage of SteraMist in Q2 2025, indicating growing market acceptance [12] Company Strategy and Development Direction - The company is focused on expanding customer outreach through targeted marketing strategies and strategic partnerships [9] - There is an emphasis on educating the market about proactive disinfection through the SteriMist Pro certified program [10] - The company aims to enhance its infrastructure by strengthening personnel in management and expanding its global distributor network [28] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about maintaining a positive trajectory for the remainder of 2025, despite challenges faced in Q2 [6] - The company anticipates significant orders from large companies as new manufacturing plants are built in the U.S. [38] - Management is hopeful that upcoming regulatory approvals will significantly impact growth [29] Other Important Information - The company was recognized as the Disinfection, Decontamination, and Disinfection Product Company of the Year for 2025 [12] - The company is developing a scalable solution to replace outdated methods in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases [21] - There is a strong pipeline of international partnerships in Europe, with pending approvals expected soon [23] Q&A Session Summary Question: Can you provide margins realized in solution sales compared to the rest of the business? - Management expressed excitement about solution sales, noting high margins and an increase in gross margins to 66% this quarter [33] Question: What opportunities arise from the strategy to bring back pharma manufacturing to the U.S.? - Management highlighted that high regulatory standards present opportunities for significant orders from large companies as new facilities are built [38] Question: Have any customers that deferred CapEx projects notified you about moving ahead? - Management indicated a significant increase in customer deposits and confirmed that at least two customers are expected to proceed with projects in 2026 [41] Question: Can you describe how SteraMist would be used if FDA approvals are obtained? - Management detailed ongoing FDA approval processes for medical devices and food safety applications, emphasizing the potential for expanded market opportunities [43][44] Question: Any new uses developed for SteraMist? - Management mentioned ongoing internal tests for new applications, including extending the shelf life of flowers, but noted hurdles to overcome before entering new industries [46]

Financial Results - For Q2 2025, net sales were $1,031,000, a decrease from $3,013,000 in Q2 2024, reflecting a decline in product sales due to deferred capital expenditures by customers [5][22] - For the first half of 2025, net sales were $2,608,000, down from $4,127,000 in the same period of 2024 [5][22] - Gross profit margin improved to 66% in Q2 2025, compared to 62% in Q2 2024, attributed to a favorable product mix [5][22] - The company reported an operating loss of $(1,133,000) for Q2 2025, compared to an income of $122,000 in Q2 2024 [5][22] - Net loss for Q2 2025 was $(1,238,000) or $(0.06) per share, compared to a net income of $30,000 or $0.00 per share in Q2 2024 [5][22] Business Highlights - Service and training revenue increased by 33% year-over-year in Q2 2025 and by 46% in the first half of 2025, indicating strong demand for decontamination services [5][6] - SteraMist solution sales rose by 40% year-over-year for the first half of 2025 [5] - The company achieved nearly 20% of Q2 revenue from international markets, demonstrating ongoing global expansion [5][6] Strategic Initiatives - The company is focused on expanding recurring service contracts and exploring new product lines to generate steady income [12] - Plans to strengthen the corporate team and expand talent in key areas such as sales and customer support are underway [9] - The company is negotiating approximately $2 million in new custom and integrated contracts, with bids expected to close before year-end [5] Leadership and Recognition - David Vanston was appointed as Chief Financial Officer in May 2025, bringing extensive experience to support growth and capital strategy [7] - The company received the "Disinfection and Decontamination Products Company of the Year" award by MedTech Outlook in June 2025, highlighting its commitment to excellence [6] Liquidity and Capital Access - As of June 30, 2025, the company had working capital of $2.8 million, with cash used in operations improving by over $1 million compared to the prior year [8] - The company completed a $435,000 convertible note financing in the first half of 2025 to support growth initiatives [8]

Core Insights - TOMI Environmental Solutions, Inc. has received significant purchase orders from a leading company in eye health, indicating strong demand for its disinfection solutions [1][4] - The total expected purchases from this customer for 2025 are approximately $385,000, which includes SteraMist iHP equipment, BIT Solution, and support services [4] Group 1: Purchase Orders and Customer Engagement - A customer placed an initial order for multiple Surface Units and disinfection carts for its South Carolina facility earlier in the year, followed by a second order for the Florida facility in Q3 2025 [2] - The successful completion of the South Carolina validation package demonstrates the effectiveness of TOMI's surface treatment solutions [2][3] Group 2: Technology and Competitive Advantage - The FDA has highlighted the need for complete decontamination of hard-to-clean equipment, which TOMI's SteraMist technology addresses effectively [3] - SteraMist has successfully passed trials against Geobacillus stearothermophilus spores, showcasing the reliability of its iHP technology [3] Group 3: Company Overview and Product Offering - TOMI Environmental Solutions specializes in disinfection and decontamination, utilizing its Binary Ionization Technology (BIT) platform, which employs low percentage hydrogen peroxide as the active ingredient [5] - The company's products are designed for a wide range of applications, including hospitals, biosafety labs, pharmaceutical facilities, and more [5]

Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, enhanced by patented ionized Hydrogen Peroxide (iHP) technology [4] - TOMI's products cater to a wide range of sectors, including hospitals, biosafety labs, pharmaceutical facilities, schools, and more [4] Financial Reporting - TOMI will report its second-quarter results for the period ending June 30, 2025, after the market closes on August 14, 2025 [1] - A conference call to discuss these results will take place at 4:30 p.m. ET on the same day [1] Participation Details - Participants can join the conference call by dialing (888) 506-0062 or (973) 528-0011 for international callers, using access code 838858 [2] - A replay of the teleconference will be available until August 28, 2025, with access codes provided for both domestic and international callers [3]

Core Insights - TOMI Environmental Solutions, Inc. has received a significant order from ARES Distribution for its SteraMist Integration System (SIS) platform, marking the fourth order for this product line [1][2] - The order is intended for a biomedical research university in Coral Gables, Florida, with an expedited delivery expected by late 2025 [2] - The COO of TOMI emphasized the importance of innovation and collaboration in the sterilization technology sector, highlighting the insights gained from each project to optimize workflow and automation capabilities [3] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its Binary Ionization Technology® (BIT™) platform, which employs low percentage hydrogen peroxide as the active ingredient [3] - The company's products are designed for a wide range of environments, including hospitals, biosafety labs, pharmaceutical facilities, and various commercial settings [3]